Focused on Cures

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients

About Our CRISPR-based Technology

Cutting-edge Therapies Designed to Eliminate Viral DNA

We have multiple CRISPR-based therapies in development targeting a variety of viral infectious diseases, including:

View Our Pipeline ProgramsView Clinical Trials

Human immunodeficiency virus (HIV)

Herpes simplex viruses (HSV 1&2)

Hepatitis B

"I am optimistic that Excision’s technology and approach using CRISPR could potentially cure infectious diseases and bring much-needed therapies to those in need around the world."

Jennifer Doudna, Ph.D., CRISPR Co-inventor

UC Berkeley, 2020

"For the first time, researchers eliminated HIV from the genomes of living animals."

TIME, 2019

Alice Park review of Excision’s technology publication in Nature Medicine, July 2019

"A new reason for increased hope that an actual cure may ultimately be found."

Francis Collins, M.D. Ph.D., NIH Director

In a review of Excision’s technology on the NIH website, 2019

"This may be a breakthrough... Such molecular biological approaches will be the future for a bona fide approach to HIV eradication and merits maximum support."

Robert Gallo, M.D., University of Maryland, Co-discoverer of HIV

Referring to Excision’s technology and work in the Khalili lab

Helping Patients Break Free from Viral Diseases

Founded in 2015, Excision BioTherapeutics is a biotechnology company leveraging proprietary, CRISPR-based gene-editing technology and collaborative partnerships with leading research institutions to develop and advance transformative therapies designed to improve the lives of patients living with viral infectious diseases.--

About Our Company